Lay Sciences' novel IgY technology is for treatment and prophylaxis
LAY SCIENCES INC. LICENSED IGY RANGE OF PRODUCTS FROM
Y PRODIGY BIOTECH
Y REAGENE BIOSCIENCES
Y KYNTOX BIOTECH
Plus years experience of each member in the Discovery Team
Headquartered in Florida, USADr. SatishCEO
Countries launch planned
Indications targeted by various products developed with IgY platform
Lay Sciences Inc. completes development and launches ImmunIgY in select markets for Covid-19 www.myimmunigy.com
Targeted oral polyclonal IgY antibodies for therapeutics and prophylaxis
Oral dosing of IgY antibodies allows for therapeutic interventions and for prophylaxis in a targeted manner.
Y Targets that were previously considered undruggable.
Oral dosing avoids systemic exposure.
Y Thereby, reduces the unpleasant side effects and loss of efficacy
Proprietary formulations that protect IgY from gastric acids and proteases.
Y Allows for release of antibodies to targeted regions of the gut.
Antibodies are metabolized similarly as other ingested proteins.
Y Thereby, safe.
Strong Experience in Drug Discovery, Development and Commercialization
Satish Chandran, Ph.D.
CEO and President
30+ years of Leadership Experience in Vaccines, Drugs, Biologics & Medical Devices
Uday Saxena, Ph.D.
30+ years of Leadership Experience in Drug Discovery
Subrahmanyam Vangala, Ph.D.
30+ years of Leadership Experience in Drug Development
Chetan M. BANGERA
30+ years of Leadership Experience in Pharma Marketing - Innovators, Generics and Biologics
Gopi Kadiyala, Ph.D.
10+ years of experience in Diagnostic and IgY technology
Subra Iyer, Ph.D.
20+ years of experience in IgY technology with Product Focus
For suggestions & inquiries